Industry
Biotechnology
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
3.61
Mkt cap
142M
Volume
48K
High
3.68
P/E Ratio
-1.69
52-wk high
6.98
Low
3.57
Div yield
N/A
52-wk low
2.47
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 4:18 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:30 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 6:59 am
Portfolio Pulse from Benzinga Insights
June 12, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 4:49 pm
Portfolio Pulse from Benzinga Insights
May 08, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.